Illinois is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device
NCT06410261
Recruiting
Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts energetic resources when carrying-out tasks of daily life and/or interacting with the community, as these require ambulatory mobility. This experience of excessive fatigue has its roots in muscle weakness... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
Register for Updates
MBC2OTP Project (Measurement-Based Care Implementation in Community Opioid Treatment Programs)
NCT06345274
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and implementation of measurement-based care, which involves the systematic use of client self-report data to inform and enhance treatment, in opioid treatment programs using a pilot hybrid effectiveness-implementation study design. The main questions this study aims to answer are: 1) is measurement based care effective for improving patient treatment attendance and opioid abstinence, and 2) can measurement based care be implemente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Family Guidance Centers, Inc., Aurora, Illinois
Conditions: Opioid Use Disorder
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Rebecca McFall, Chicago, Illinois
Conditions: Neuroblastoma
Register for Updates
Optimal Timing for Spontaneous Breathing Trials
NCT06561295
Recruiting
This study aims to explore how the timing of Spontaneous Breathing Trials (SBTs) affects recovery in adult patients who are on mechanical ventilation in the ICU. SBTs are tests used to determine if a patient is ready to breathe on their own without the help of a ventilator. The study will compare two different timing strategies for these trials: one group of patients will have the test early in the morning, while the other group will have it later in the morning. By observing the outcomes, such... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
09/17/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Respiration, Artificial, Weaning
Register for Updates
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
NCT04561206
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Relapsed Classic Hodgkin Lymphoma
Register for Updates
Kidney Stone Inflammation
NCT06436235
Recruiting
This observational study aims to look at the connections between kidney stones, insulin resistance, and inflammation. The researchers hypothesize that people who form calcium kidney stones and have insulin resistance may have higher levels of inflammation because they have more visceral fat (fat around the abdominal organs). The study will recruit 20 people who have had calcium kidney stones but don't have diabetes, and 20 healthy people who haven't had kidney stones. All the participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/16/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Kidney Stone, Stone, Kidney
Register for Updates
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
NCT06305286
Recruiting
AT-1501 is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the subject's immune system to attack and fight foreign substances that cause illness. Monoclonal antibodies are man-made proteins manufactured to serve as substitute antibodies to fight diseases. Monoclonal antibodies can restore, enhance, or mimic (copy) the immune system's attack process; they can also tone down the immune system. AT-1501 is thought to work by dampening down the immune system so... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/16/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Diabetes Mellitus
Register for Updates
Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.
NCT05516537
Recruiting
The proposed project involves a high-quality randomized controlled (RCT) design that examines the effects of a remotely-delivered, racially-tailored exercise training program for immediate and sustained improvement in walking dysfunction, symptoms, and health-related quality of life (HRQOL) among African-Americans with MS residing in rural environments. The primary analysis will test the hypothesis that those who are randomly assigned into the intervention condition (i.e., exercise training) wil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
Register for Updates
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT03013998
Recruiting
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negativ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Register for Updates
Time-restricted Eating Among Pregnant Females With Severe Obesity
NCT06477120
Recruiting
In the United States, severe obesity (body mass index (BMI) ≥ 40.0 kg/m2) affects approximately 10% of females of reproductive age with Black females disproportionately burdened (16%). Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, birth defects and a three-fold greater risk of maternal mortality - outcomes that also disproportionately affect Black females. Obser... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
09/13/2024
Locations: University of Illinois at Chicago College of Applied Health Sciences, Chicago, Illinois
Conditions: Obesity, Morbid, Time Restricted Eating, Pregnancy Weight Gain
Register for Updates
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
NCT06456567
Recruiting
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Gender:
ALL
Ages:
Between 12 years and 70 years
Trial Updated:
09/13/2024
Locations: Rockford site, Rockford, Illinois
Conditions: Systemic Lupus Erythematosus
Register for Updates
Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago)
NCT05521607
Recruiting
A cross-sectional conductive study at the University of Chicago Medicine facilities (hospital and outreach clinics) to enable high qualitative estimation of bilirubin levels in the blood of newborns, independent of skin color, using Picterus JP.
Gender:
ALL
Ages:
Between 1 day and 14 days
Trial Updated:
09/13/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Neonatal Jaundice
Register for Updates